Search

Your search keyword '"Rejto, Paul A."' showing total 111 results
Start Over Author "Rejto, Paul A." Publication Year Range Last 10 years
111 results on '"Rejto, Paul A."'

1. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Author

Park, Yeon Hee, Im, Seock-Ah, Park, Kyunghee, Wen, Ji, Lee, Kyung-Hun, Choi, Yoon-La, Lee, Won-Chul, Min, Ahrum, Bonato, Vinicius, Park, Seri, Ram, Sripad, Lee, Dae-Won, Kim, Ji-Yeon, Lee, Su Kyeong, Lee, Won-Woo, Lee, Jisook, Kim, Miso, Kim, Hyun Seon, Weinrich, Scott L., Ryu, Han Suk, Kim, Tae Yong, Dann, Stephen, Kim, Yu-Jin, Fernandez, Diane R., Koh, Jiwon, Wang, Shuoguo, Park, Song Yi, Deng, Shibing, Powell, Eric, Ravi, Rupesh Kanchi, Bienkowska, Jadwiga, Rejto, Paul A., Park, Woong-Yang, and Kan, Zhengyan

Published
2023
Full Text
View/download PDF

2. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib

Author

Zhu, Zhou, Turner, Nicholas C., Loi, Sherene, André, Fabrice, Martin, Miguel, Diéras, Véronique, Gelmon, Karen A., Harbeck, Nadia, Zhang, Cathy, Cao, Joan Q., Yan, Zhengming, Lu, Dongrui R., Wei, Ping, VanArsdale, Todd L., Rejto, Paul A., Huang, Xin, Rugo, Hope S., Loibl, Sibylle, Cristofanilli, Massimo, Finn, Richard S., and Liu, Yuan

Published
2022
Full Text
View/download PDF

3. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy

Author

Maresca, Kevin P., Chen, Jianqing, Mathur, Divya, Giddabasappa, Anand, Root, Adam, Narula, Jatin, King, Lindsay, Schaer, David, Golas, Jonathan, Kobylarz, Keith, Rosfjord, Edward, Keliher, Edmund, Chen, Laigao, Ram, Sripad, Pickering, Eve H., Hardwick, James S., Rejto, Paul A., Hussein, Amira, Ilovich, Ohad, Staton, Kevin, Wilson, Ian, and McCarthy, Timothy J.

Published
2021
Full Text
View/download PDF

4. Pancreatic Cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for Pancreatic Cancer

Author

Abdilleh, Kawther, primary, Khalid, Omar, additional, Ladnier, Dennis, additional, Wan, Wenshuai, additional, Seepo, Sara, additional, Rupp, Garrett, additional, Corelj, Valentin, additional, Worman, Zelia F., additional, Sain, Divya, additional, DiGiovanna, Jack, additional, Press, Bruce, additional, Chandrashekhar, Satty, additional, Collisson, Eric, additional, Cui, Karen Y., additional, Maitra, Anirban, additional, Rejto, Paul A., additional, White, Kevin P., additional, Matrisian, Lynn, additional, and Doss, Sudheer, additional

Published
2024
Full Text
View/download PDF

6. Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome

Author

Park, Yeon Hee, Lal, Samir, Lee, Jeong Eon, Choi, Yoon-La, Wen, Ji, Ram, Sripad, Ding, Ying, Lee, Soo-Hyeon, Powell, Eric, Lee, Se Kyung, Yu, Jong Han, Ching, Keith A., Nam, Jae-Yong, Kim, Seok Won, Nam, Seok Jin, Kim, Ji-Yeon, Cho, Soo Youn, Park, Seri, Kim, Jinho, Hwang, Soohyn, Kim, Yu Jin, Bonato, Vinicius, Fernandez, Diane, Deng, Shibing, Wang, Shuoguo, Shin, Hyuntae, Kang, Eun-Suk, Park, Woong-Yang, Rejto, Paul A., Bienkowska, Jadwiga, and Kan, Zhengyan

Published
2020
Full Text
View/download PDF

8. Supplementary Table 4 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

9. Data from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

11. Data from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table 2 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table 2 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Information from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure Legend from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure Legends 1-3, Table Legends 1-4 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Material: DLDA Classifier IGF Signature from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Material: DLDA classifiers IGF Pathway Score from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 4 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 1 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 3 from An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Author

Hook, Kenneth E., primary, Garza, Scott J., primary, Lira, Maruja E., primary, Ching, Keith A., primary, Lee, Nathan V., primary, Cao, Joan, primary, Yuan, Jing, primary, Ye, Jingjing, primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, Christensen, James G., primary, and Pavlicek, Adam, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 3 from Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Author

Pavlicek, Adam, primary, Lira, Maruja E., primary, Lee, Nathan V., primary, Ching, Keith A., primary, Ye, Jingjing, primary, Cao, Joan, primary, Garza, Scott J., primary, Hook, Kenneth E., primary, Ozeck, Mark, primary, Shi, Stephanie T., primary, Yuan, Jing, primary, Zheng, Xianxian, primary, Rejto, Paul A., primary, Kan, Julie L.C., primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figures 1-13 from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

Author

Wang, Kai, primary, Zhang, Qin, primary, Li, Danan, primary, Ching, Keith, primary, Zhang, Cathy, primary, Zheng, Xianxian, primary, Ozeck, Mark, primary, Shi, Stephanie, primary, Li, Xiaorong, primary, Wang, Hui, primary, Rejto, Paul, primary, Christensen, James, primary, and Olson, Peter, primary

Published
2023
Full Text
View/download PDF

28. Supplemental Materials and Methods from PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor

Author

Wang, Kai, primary, Zhang, Qin, primary, Li, Danan, primary, Ching, Keith, primary, Zhang, Cathy, primary, Zheng, Xianxian, primary, Ozeck, Mark, primary, Shi, Stephanie, primary, Li, Xiaorong, primary, Wang, Hui, primary, Rejto, Paul, primary, Christensen, James, primary, and Olson, Peter, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Methods from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

Author

Zhang, Cathy C., primary, Pavlicek, Adam, primary, Zhang, Qin, primary, Lira, Maruja E., primary, Painter, Cory L., primary, Yan, Zhengming, primary, Zheng, Xianxian, primary, Lee, Nathan V., primary, Ozeck, Mark, primary, Qiu, Ming, primary, Zong, Qing, primary, Lappin, Patrick B., primary, Wong, Anthony, primary, Rejto, Paul A., primary, Smeal, Tod, primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figures 1 - 5 from Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models

Author

Zhang, Cathy C., primary, Pavlicek, Adam, primary, Zhang, Qin, primary, Lira, Maruja E., primary, Painter, Cory L., primary, Yan, Zhengming, primary, Zheng, Xianxian, primary, Lee, Nathan V., primary, Ozeck, Mark, primary, Qiu, Ming, primary, Zong, Qing, primary, Lappin, Patrick B., primary, Wong, Anthony, primary, Rejto, Paul A., primary, Smeal, Tod, primary, and Christensen, James G., primary

Published
2023
Full Text
View/download PDF

31. Additional file 6 of Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Author

Park, Yeon Hee, Im, Seock-Ah, Park, Kyunghee, Wen, Ji, Lee, Kyung-Hun, Choi, Yoon-La, Lee, Won-Chul, Min, Ahrum, Bonato, Vinicius, Park, Seri, Ram, Sripad, Lee, Dae-Won, Kim, Ji-Yeon, Lee, Su Kyeong, Lee, Won-Woo, Lee, Jisook, Kim, Miso, Kim, Hyun Seon, Weinrich, Scott L., Ryu, Han Suk, Kim, Tae Yong, Dann, Stephen, Kim, Yu-Jin, Fernandez, Diane R., Koh, Jiwon, Wang, Shuoguo, Park, Song Yi, Deng, Shibing, Powell, Eric, Ravi, Rupesh Kanchi, Bienkowska, Jadwiga, Rejto, Paul A., Park, Woong-Yang, and Kan, Zhengyan

Abstract

Additional file 6. Fig. S1. Kaplan-Meier plots of poor prognostic biomarkers. Fig. S2. Characteristics of the HRD-high cluster. Fig. S3. Characteristics of HRD-high tumors co-occurring with TP53 mutation. Fig. S4. Kaplan-Meier plots of expression-based prognosis markers. Fig. S5. Proliferative cluster enriched in poor prognostic markers. Fig. S6. Integrative analysis identified distinct prognostic clusters. Fig. S7. Molecular characteristics of integrative clusters. Fig. S8. Subtype switching driven by changes in PAM50 score composition. Fig. S9. Increased tumor growth and proliferation at PD. Fig. S10. IHC analysis of cell cycle markers. Fig. S11. Landscape of PD-specific genomic alterations. Fig. S12. RB1 LOF associated with increased APOBEC signature at PD. Fig. S13. APOBEC signature enriched in PD-specific tumor subclones.

Published
2023
Full Text
View/download PDF

32. Abstract A008: PanCAN SPARK: A cloud-based health data integration platform for pancreatic cancer data

Author

Abdilleh, Kawther, primary, Khalid, Omar, additional, Ladnier, Dennis, additional, Wan, Wenshuai, additional, Seepo, Sara, additional, Rupp, Garrett, additional, Corelj, Valentin, additional, Worman, Zelia F., additional, Press, Bruce, additional, DiGiovanna, Jack, additional, Chandrashekhar, Satty, additional, Collisson, Eric, additional, Cui, Karen, additional, Maitra, Anirban, additional, Rejto, Paul A., additional, White, Kevin, additional, Matrisian, Lynn, additional, and Doss, Sudheer, additional

Published
2022
Full Text
View/download PDF

33. Abstract PD2-08: Serial genomic profiling reveals molecular mechanisms of breast cancer resistance to palbociclib

Author

Kan, Zhengyan, primary, Im, Seock-Ah, additional, Park, Kyunghee, additional, Wen, Ji, additional, Lee, Kyung-Hun, additional, Choi, Yoon-La, additional, Lee, Won-Chul, additional, Min, Ahrum, additional, Bonato, Vinicius, additional, Park, Seri, additional, Ram, Sripad, additional, Lee, Dae-Won, additional, Kim, Ji-Yeon, additional, Lee, Su Kyeong, additional, Lee, Won-Woo, additional, Lee, Jisook, additional, Kim, Miso, additional, Weinrich, Scott L., additional, Ryu, Han Suk, additional, Kim, Tae Yong, additional, Dann, Stephen, additional, Fernandez, Diane, additional, Koh, Jiwon, additional, Park, Song Yi, additional, Deng, Shibing, additional, Powell, Eric, additional, Ravi, Rupesh Kanchi, additional, Bienkowska, Jadwiga, additional, Rejto, Paul A., additional, Park, Woong-Yang, additional, and Park, Yeon Hee, additional

Published
2022
Full Text
View/download PDF

34. MOESM2 of Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

Author

Wenyan Zhong, Myers, Jeremy, Wang, Fang, Wang, Kai, Lucas, Justin, Rosfjord, Edward, Lucas, Judy, Hooper, Andrea, Yang, Sharon, Lemon, Lu, Guffroy, Magali, May, Chad, Bienkowska, Jadwiga, and Rejto, Paul

Abstract

Additional file 2: Figure S1. Mutation landscape of syngeneic models and types of somatic variants for each model. Figure S2. A. Ratio of Ts (Transition) to Tv (Transversion) substitution mutation in each syngeneic model; dashed lines represent maximum, median and minimum of median Ts/Tv from each human tumor types (data from (Alexandrov et al. 2013)) respectively. B. Single nucleotide mutation changes in each syngeneic model. Figure S3. E-cadherin and vimentin stain in syngeneic models. Figure S4. A. Correlation of neoantigen with mutational load in syngeneic models. B. Correlation of neoantigen with cytolytic activity in syngeneic models. The correlation was calculated using spearman method in R. numMutation: number of missense mutation. Figure S5. Response of syngeneic tumor models to anti-CTLA4, or anti PD-1. All mice were dosed intravenously. Individual tumor volumes are shown for 10 mice treated with PBS (black) or 10 mg/kg anti-CTLA4 (9H10) (red trace), or 10 mg/kg anti-PD-1 (RMP 1–14) (blue trace). All 10 mice bearing CT26 tumors dosed with anti-CTLA4 had no measurable tumor from study day 25 until measurements ended on study day 238. Comparison of mean tumor volumes was analyzed using log-transformed ANOVA. P-values are shown if there was a statistical difference between vehicle and antibody-treated groups. n.s. not significant. Figure S6. A. Expression of Gzma and Prf1 in syngeneic model grown in vitro (Cell) and in vivo (Tissue) across models based on protein expression. B. Cytolytic activity of syngeneic models. Cytolytic activity (CYT) is defined as the log-average (geometric mean) of Gzma and Prf1 protein expression. C. Protein expression of Gzma in soluble fraction. LFQ: label free quantitation. Figure S7. Gene expression of β-catenin, β-catenin target genes (gene list from (Spranger et al. 2015)) and epigenetic modulators (Ezh2, Dnmt1) across syngeneic models. Figure S8. CTLA4 expression in syngeneic in vivo tumor samples.

Published
2020
Full Text
View/download PDF

36. Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.

Author

Maresca, Kevin P., Chen, Jianqing, Mathur, Divya, Giddabasappa, Anand, Root, Adam, Narula, Jatin, King, Lindsay, Schaer, David, Golas, Jonathan, Kobylarz, Keith, Rosfjord, Edward, Keliher, Edmund, Chen, Laigao, Ram, Sripad, Pickering, Eve H., Hardwick, James S., Rejto, Paul A., Hussein, Amira, Ilovich, Ohad, and Staton, Kevin

Subjects
POSITRON emission tomography, T cells, COMPUTED tomography, BISPECIFIC antibodies, CELLULAR therapy, COLORECTAL cancer
Abstract

Purpose: A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging bispecific antibody that binds to CD3 and guanylyl cyclase C, a protein that is over-expressed by colorectal cancers. Here, we used 89Zr-Df-IAB22M2C (89Zr-Df-Crefmirlimab), a human CD8-specific minibody to monitor CD8+ T cell infiltration into tumors by positron emission tomography. We investigated the ability of 89Zr-Df-IAB22M2C to track anti-tumor activity induced by PF-07062119 in a human CRC adoptive transfer mouse model (with injected activated/expanded human T cells), as well as the correlation of tumor radiotracer uptake with CD8+ immunohistochemical staining. Procedures: NOD SCID gamma mice bearing human CRC LS1034 tumors were treated with four different doses of PF-07062119, or a non-targeted CD3 BsAb control, and imaged with 89Zr-Df-IAB22M2C PET at days 4 and 9. Following PET/CT imaging, mice were euthanized and dissected for ex vivo distribution analysis of 89Zr-Df-IAB22M2C in tissues on days 4 and 9, with additional data collected on day 6 (supplementary). Data were analyzed and reported as standard uptake value and %ID/g for in vivo imaging and ex vivo tissue distribution. In addition, tumor tissues were evaluated by immunohistochemistry for CD8+ T cells. Results: The results demonstrated substantial mean uptake of 89Zr-Df-IAB22M2C (%ID/g) in PF-07062119-treated tumors, with significant increases in comparison to non-targeted BsAb-treated controls, as well as PF-07062119 dose-dependent responses over time of treatment. A moderate correlation was observed between tumor tissue radioactivity uptake and CD8+ cell density, demonstrating the value of the imaging agent for non-invasive assessment of intra-tumoral CD8+ T cells and the mechanism of action for PF-07062119. Conclusion: Immune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of 89Zr-IAB22M2C PET to evaluate PD responses (mice) to a novel immunotherapeutic. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Molecular and cellular phenotypic differences distinguish murine syngeneic models from human tumors

Author

Zhong, Wenyan, primary, Myers, Jeremy S., additional, Wang, Fang, additional, Wang, Kai, additional, Lucas, Justin, additional, Rosfjord, Edward, additional, Lucas, Judy, additional, Hooper, Andrea T., additional, Yang, Sharon, additional, Lemon, LuAnna, additional, Guffroy, Magali, additional, May, Chad, additional, Bienkowska, Jadwiga R., additional, and Rejto, Paul A., additional

Published
2019
Full Text
View/download PDF

38. Abstract 1684: Multi-omics profiling of breast cancers during neoadjuvant chemotherapy identified distinct molecular changes and biomarkers associated with clinical response

Author

Lal, Samir, primary, Ding, Ying, additional, Lee, Jeong Eon, additional, Lee, Soo-Hyeon, additional, Lee, Se Kyung, additional, Nam, Jae-Yong, additional, Yu, Jong Han, additional, Choi, Yoon-la, additional, Kim, Seok Won, additional, Nam, Seok Jin, additional, Kim, Ji-Yeon, additional, Ram, Sripad, additional, Powell, Eric, additional, Ching, Keith A., additional, Tamayo, Pablo, additional, Kim, William, additional, Yeerna, Huwate, additional, Cho, Soo Youn, additional, Bonato, Vinicius, additional, Deng, Shibing, additional, Kim, Jinho, additional, Shin, Hyuntae, additional, Park, Woong-Yang, additional, Rejto, Paul A., additional, Bienkowska, Jadwiga, additional, Park, Yeon-Hee, additional, and Kan, Zhengyan, additional

Published
2019
Full Text
View/download PDF

42. Abstract 2355: Palbociclib enhances the antitumor activity of taxanes by abrogating cell cycle checkpoints and alleviating hypoxia in squamous cell lung cancer

Author

Cao, Joan, primary, Zhu, Zhou, additional, Wang, Hui, additional, Nichols, Tim, additional, Rosfjord, Edward, additional, Hopf, Christine, additional, Upeslacis, Erik, additional, Rejto, Paul, additional, Weinrich, Scott, additional, Vanarsdale, Todd, additional, Hardwick, James, additional, and Wei, Ping, additional

Published
2017
Full Text
View/download PDF

43. Abstract 2749: Liquid biopsy testing allows highly-sensitive detection of plasma cfDNA mutations in 87 breast cancer-related genes

Author

Lira, Maruja E., primary, Xie, Tao, additional, Deng, Shibing, additional, Kinong, Jennifer, additional, Gao, Jingjin, additional, Zhu, Zhou, additional, Lee, Nathan, additional, Rejto, Paul, additional, Bienkowska, Jadwiga, additional, Hardwick, James, additional, Wang, Kai, additional, and Huang, Stephen, additional

Published
2017
Full Text
View/download PDF

45. TNER: a novel background error suppression method for mutation detection in circulating tumor DNA.

Author

Shibing Deng, Donghui Huang, Kai Wang, Valdez, Crystal, Kinong, Jennifer, Rejto, Paul A., Bienkowska, Jadwiga, Hardwick, James, and Tao Xie

Subjects
CIRCULATING tumor DNA, GENETIC mutation, DISEASE progression, ERRORS, EARLY detection of cancer
Abstract

Background: Ultra-deep next-generation sequencing of circulating tumor DNA (ctDNA) holds great promise as a tool for the early detection of cancer and for monitoring disease progression and therapeutic responses. However, the low abundance of ctDNA in the bloodstream coupled with technical errors introduced during library construction and sequencing complicates mutation detection. Results: To achieve high accuracy of variant calling via better distinguishing low-frequency ctDNA mutations from background errors, we introduce TNER (Tri-Nucleotide Error Reducer), a novel background error suppression method that provides a robust estimation of background noise to reduce sequencing errors. The results on both simulated data and real data from healthy subjects demonstrate that the proposed algorithm consistently outperforms a current, state-of-the-art, position-specific error polishing model, particularly when the sample size of healthy subjects is small. Conclusions: TNER significantly enhances the specificity of downstream ctDNA mutation detection without sacrificing sensitivity. The tool is publicly available at https://github.com/ctDNA/TNER. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

48. OASIS: web-based platform for exploring cancer multi-omics data

Author

Fernandez-Banet, Julio, primary, Esposito, Anthony, additional, Coffin, Scott, additional, Horvath, Istvan Boerner, additional, Estrella, Heather, additional, Schefzick, Sabine, additional, Deng, Shibing, additional, Wang, Kai, additional, AChing, Keith, additional, Ding, Ying, additional, Roberts, Peter, additional, Rejto, Paul A, additional, and Kan, Zhengyan, additional

Published
2015
Full Text
View/download PDF

50. Abstract A42: Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma

Author

Hidalgo, Manuel, primary, Menendez, Camino, additional, Yuan, Jing, additional, Salvador, Beatriz, additional, Xie, Tao, additional, Chionis, John, additional, Lopez-Casas, Pedro, additional, Zheng, Xianxian, additional, Hardwick, James, additional, Rejto, Paul, additional, Olson, Peter, additional, VanArsdale, Todd, additional, and Shields, David J., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results